From Clinical Trials to Clinical Implications: PARP Inhibitor Combinations in Advanced Prostate Cancer

Target Audience
This activity was developed for medical oncologists and other healthcare professionals involved in the treatment of prostate cancer.

Program Overview

CONTENT AREAS

Testing
PARP inhibitor mechanism of action
Olaparib clinical trials
Rucaparib clinical trials
PARP inhibitor combination therapy

Learning Objectives
Upon completion of this activity, participants should be better able to:

Discuss new and emerging data on PARP inhibitors in combination with other therapies for the treatment of advanced PC
Identify patients who may benefit from the use of PARP inhibitors combinations for the treatment of advanced PC based on the latest evidence